Merck, Inc.
🇵🇭Philippines
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3000
- Registration Number
- NCT00095576
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 91
- Registration Number
- NCT00095056
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-10-25
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 521
- Registration Number
- NCT00094757
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
- First Posted Date
- 2004-10-25
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1172
- Registration Number
- NCT00094770
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 216
- Registration Number
- NCT00093080
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5759
- Registration Number
- NCT00092521
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT00092300
A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT00092846
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12167
- Registration Number
- NCT00092534
A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT00092859
© Copyright 2024. All Rights Reserved by MedPath